Domain Therapeutics

About:

Domain Therapeutics develops small molecules targeting G-coupled protein receptors.

Website: http://www.domaintherapeutics.com

Twitter/X: domaintherapeut

Top Investors: Andera Partners, Bpifrance, Seventure Partners, adMare Bio Innovations, Airfi aero

Description:

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Total Funding Amount:

$100M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Illkirch, Alsace, France

Founded Date:

2001-01-01

Contact Email:

contact(AT)domaintherapeutics.com

Founders:

Pascal Neuville

Number of Employees:

101-250

Last Funding Date:

2024-01-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai